poisar

Stocks · News reference

BioCryst to Present New Data for ORLADEYO and Navenibart at ACAAI Annual Scientific Meeting

Fiscal.ai

BioCryst Pharmaceuticals announced it will present new clinical data regarding its HAE therapy ORLADEYO and its investigational candidate Navenibart at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — BIOCRYST PHARMACEUTICALS INC (BCRX)

    Filed: 2026-11-04 AccNo: 0001171843-26-007097 Size: 451 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits